Alnylam Pharmaceuticals Inc.

164.01+2.65+1.64%Vol 721.20K1Y Perf -21.21%
Nov 29th, 2023 16:00 DELAYED
BID150.50 ASK165.00
Open161.79 Previous Close161.36
Pre-Market- After-Market164.01
 - -  - -%
Target Price
244.26 
Analyst Rating
Moderate Buy 1.68
Potential %
48.93 
Finscreener Ranking
★★     45.81
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
+     37.15
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
     36.88
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
16.77 
Earnings Rating
Strong Buy
Market Cap20.58B 
Earnings Date
2nd Nov 2023
Alpha0.01 Standard Deviation0.12
Beta0.47 

Today's Price Range

160.18164.19

52W Range

148.10242.97

5 Year PE Ratio Range

-16.60-16.60

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
0.69%
1 Month
8.32%
3 Months
-16.81%
6 Months
-12.04%
1 Year
-21.21%
3 Years
26.25%
5 Years
102.08%
10 Years
167.99%

TickerPriceChg.Chg.%
ALNY164.012.65001.64
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
3.20
3.50
0.84
5.63
-6.20
Leverage Ratio 21.40
ProfitabilityValueIndustryS&P 500US Markets
83.90
-105.90
-97.30
-447.70
-97.99
RevenueValueIndustryS&P 500US Markets
702.38M
5.71
96.76
73.44
Earnings HistoryEstimateReportedSurprise %
Q03 2023-1.611.15171.43
Q02 2023-1.72-2.21-28.49
Q01 2023-1.97-1.4028.93
Q04 2022-2.13-1.6821.13
Q03 2022-1.86-3.32-78.49
Q02 2022-1.62-2.29-41.36
Q01 2022-1.93-2.00-3.63
Q04 2021-1.47-2.16-46.94
Earnings Per EndEstimateRevision %Trend
12/2023 QR-1.3321.76Positive
12/2023 FY-3.7444.92Positive
3/2024 QR-1.5011.24Positive
12/2024 FY-5.15-43.85Negative
Next Report Date-
Estimated EPS Next Report-1.61
Estimates Count10
EPS Growth Next 5 Years %-
Volume Overview
Volume721.20K
Shares Outstanding125.49K
Shares Float123.74M
Trades Count14.11K
Dollar Volume117.61M
Avg. Volume510.16K
Avg. Weekly Volume363.13K
Avg. Monthly Volume538.17K
Avg. Quarterly Volume629.19K

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) stock closed at 164.01 per share at the end of the most recent trading day (a 1.64% change compared to the prior day closing price) with a volume of 721.20K shares and market capitalization of 20.58B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1453 people. Alnylam Pharmaceuticals Inc. CEO is John M. Maraganore.

The one-year performance of Alnylam Pharmaceuticals Inc. stock is -21.21%, while year-to-date (YTD) performance is -30.99%. ALNY stock has a five-year performance of 102.08%. Its 52-week range is between 148.1 and 242.97, which gives ALNY stock a 52-week price range ratio of 16.77%

Alnylam Pharmaceuticals Inc. currently has a PE ratio of -23.00, a price-to-book (PB) ratio of 142.92, a price-to-sale (PS) ratio of 38.49, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -36.50%, a ROC of -78.71% and a ROE of -412.82%. The company’s profit margin is -97.99%, its EBITDA margin is -97.30%, and its revenue ttm is $702.38 Million , which makes it $5.71 revenue per share.

Of the last four earnings reports from Alnylam Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.61 for the next earnings report. Alnylam Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Alnylam Pharmaceuticals Inc. is Moderate Buy (1.68), with a target price of $244.26, which is +48.93% compared to the current price. The earnings rating for Alnylam Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alnylam Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alnylam Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.77, ATR14 : 5.90, CCI20 : -49.79, Chaikin Money Flow : 0.01, MACD : -1.32, Money Flow Index : 35.38, ROC : -4.75, RSI : 45.15, STOCH (14,3) : 27.69, STOCH RSI : 0.46, UO : 37.42, Williams %R : -72.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alnylam Pharmaceuticals Inc. in the last 12-months were: Akshay K. Vaishnaw (Option Excercise at a value of $2 247 457), Akshay K. Vaishnaw (Sold 44 493 shares of value $9 435 774 ), Amy W. Schulman (Option Excercise at a value of $0), Ausiello Dennis (Option Excercise at a value of $0), Bonney Michael (Option Excercise at a value of $0), Bonney Michael (Sold 6 448 shares of value $1 195 310 ), David E.I. Pyott (Option Excercise at a value of $0), Dennis A. Ausiello (Option Excercise at a value of $0), Fanucci Marsha (Option Excercise at a value of $0), Garg Pushkal (Option Excercise at a value of $241 125), Garg Pushkal (Sold 22 366 shares of value $4 460 850 ), Greenstreet Yvonne (Sold 7 615 shares of value $1 481 811 ), Hamburg Margaret (Option Excercise at a value of $0), Indrani Lall Franchini (Option Excercise at a value of $0), Indrani Lall Franchini (Sold 5 175 shares of value $1 113 562 ), Margaret A. Hamburg (Option Excercise at a value of $0), Marsha H. Fanucci (Option Excercise at a value of $0), Pushkal Garg (Option Excercise at a value of $241 125), Pushkal Garg (Sold 18 072 shares of value $3 614 400 ), Pyott David (Option Excercise at a value of $0), Schulman Amy (Option Excercise at a value of $0), Tanguler Tolga (Option Excercise at a value of $0), Tanguler Tolga (Sold 5 548 shares of value $1 221 563 ), Tolga Tanguler (Option Excercise at a value of $0), Tolga Tanguler (Sold 5 025 shares of value $1 156 692 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
15 (60.00 %)
15 (62.50 %)
16 (69.57 %)
Moderate Buy
3 (12.00 %)
3 (12.50 %)
2 (8.70 %)
Hold
7 (28.00 %)
6 (25.00 %)
5 (21.74 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.68
Moderate Buy
1.63
Strong Buy
1.52

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

CEO: John M. Maraganore

Telephone: +1 617 551-8200

Address: 675 West Kendall Street, Cambridge 02142, MA, US

Number of employees: 1 453

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

58%42%

Bearish Bullish

60%40%

 

TipRanks News for ALNY

Tue, 07 Nov 2023 13:16 GMT Alnylam Pharma (ALNY) Receives a Hold from Oppenheimer

- TipRanks. All rights reserved.

Tue, 07 Nov 2023 02:12 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Baxter International (BAX), Alnylam Pharma (ALNY) and Insulet (PODD)

- TipRanks. All rights reserved.

Tue, 10 Oct 2023 17:06 GMT Alnylam Pharma: Rapid Growth and Market Potential in ATTR Sector A Buy Rating Analysis

- TipRanks. All rights reserved.

Tue, 10 Oct 2023 09:01 GMT Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Reneo Pharmaceuticals (RPHM)

- TipRanks. All rights reserved.

Mon, 09 Oct 2023 22:25 GMT Analyst Upholds Buy Rating on Alnylam Pharma Despite FDA Rejection: Future Prospects Remain Promising

- TipRanks. All rights reserved.

Mon, 09 Oct 2023 18:37 GMT Hold Rating on Alnylam Pharma Amidst Onpattros Discontinued Development and Shift Towards Amvuttra: Revised Revenue Forecast and Price Target

- TipRanks. All rights reserved.

Fri, 08 Sep 2023 00:45 GMT Alnylam Pharma (ALNY) Receives a Buy from Chardan Capital

- TipRanks. All rights reserved.

Fri, 25 Aug 2023 21:03 GMT Alnylam intends to appeal ruling on two patents asserted against Moderna

- TipRanks. All rights reserved.

Tue, 25 Jul 2023 12:30 GMT Analysts Top Healthcare Picks: Alnylam Pharma (ALNY), Biogen (BIIB)

- TipRanks. All rights reserved.

Mon, 24 Jul 2023 23:00 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY) and Exelixis (EXEL)

- TipRanks. All rights reserved.

Mon, 24 Jul 2023 22:50 GMT Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Biogen (BIIB) and Johnson & Johnson (JNJ)

- TipRanks. All rights reserved.

Tue, 18 Jul 2023 06:45 GMT Alnylam Pharma (ALNY) Gets a Buy from Bernstein

- TipRanks. All rights reserved.

Mon, 17 Jul 2023 17:05 GMT Alnylam Pharma (ALNY) Gets a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits